- Published on
Medicine – Drug Therapies in HIV Infection
Drug treatment of human immunodeficiency virus (HIV) infection has two major objectives: suppression of viral replication through antiretroviral therapy (ART) and prevention of opportunistic infections in patients with significant immunosuppression.
- Antiretroviral therapy (ART).
- Prevention of opportunistic infections.
- Monitoring treatment response and adverse effects.
- Management of drug interactions and resistance.
1. Overview of HIV Drug Therapy
2. Antiretroviral Therapy (ART)
A. When Should ART Be Started?
Older HIV treatment guidelines recommended starting antiretroviral therapy when the CD4 count fell below 350 cells/mm³ or when the viral load was particularly high.
This approach is now outdated.
ART is recommended for all people diagnosed with HIV, regardless of CD4 count or viral load, and should generally be initiated as soon as feasible.
Benefits of Early ART
- Prevents progression to AIDS.
- Reduces opportunistic infections.
- Reduces HIV-associated malignancies.
- Preserves and restores CD4+ T-cell function.
- Improves life expectancy.
- Prevents sexual transmission when sustained viral suppression is achieved.
ART timing requires special consideration in selected opportunistic infections, particularly cryptococcal meningitis and tuberculosis meningitis, because early treatment may increase the risk of serious immune reconstitution inflammatory syndrome (IRIS).
B. Aims of ART
The primary aim of ART is to achieve and maintain suppression of plasma HIV RNA to undetectable levels on standard clinical assays.
Additional Objectives
- Restore immune function.
- Increase or preserve CD4 count.
- Prevent progression to AIDS.
- Reduce morbidity and mortality.
- Prevent HIV transmission.
- Improve long-term quality of life.
Illustration: Effects of ART
ART does not eradicate HIV because the virus persists in long-lived cellular reservoirs. Consequently, treatment is generally lifelong.
C. Combination Therapy
Traditional HIV treatment used combinations of three or sometimes four antiretroviral drugs.
Most contemporary initial regimens use three active drugs from at least two drug classes.
A common regimen consists of:
- Two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).
- One integrase strand transfer inhibitor (INSTI).
Selected patients may receive recommended two-drug regimens, such as dolutegravir plus lamivudine, when appropriate eligibility criteria are met.
Advantages of Combination Therapy
- Potent suppression of viral replication.
- Reduced emergence of drug resistance.
- Improved immune recovery.
- Reduced HIV-associated complications.
3. Classes of Antiretroviral Drugs
A. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
NRTIs inhibit HIV reverse transcriptase, the enzyme responsible for converting viral RNA into DNA.
They act as defective nucleotide building blocks, causing termination of viral DNA synthesis.
Examples
- Zidovudine (AZT).
- Lamivudine (3TC).
- Emtricitabine (FTC).
- Abacavir (ABC).
- Tenofovir disoproxil fumarate (TDF).
- Tenofovir alafenamide (TAF).
Important Adverse Effects
| Drug | Important Adverse Effects or Precautions |
|---|---|
| Zidovudine | Anaemia, neutropenia, myopathy |
| Lamivudine | Generally well tolerated |
| Abacavir | Hypersensitivity; HLA-B*57:01 testing required before use |
| Tenofovir DF | Renal toxicity, reduced bone mineral density |
| Tenofovir AF | Less renal and bone toxicity than TDF; different metabolic effects |
Older NRTIs may cause mitochondrial toxicity, including lactic acidosis and pancreatitis.
B. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
NNRTIs inhibit reverse transcriptase by binding to an allosteric site on the enzyme.
Unlike NRTIs, they do not require intracellular phosphorylation to become active.
Examples
- Nevirapine.
- Efavirenz.
- Rilpivirine.
- Doravirine.
- Etravirine.
Important Adverse Effects
- Skin rash.
- Hepatotoxicity.
- Drug interactions.
- Neuropsychiatric effects, particularly with efavirenz.
Nevirapine can cause severe hepatotoxicity and hypersensitivity reactions.
C. Protease Inhibitors (PIs)
Protease inhibitors block the HIV protease enzyme, preventing cleavage of viral polyproteins into functional proteins.
This produces immature, noninfectious viral particles.
Examples
- Darunavir.
- Atazanavir.
- Lopinavir.
- Ritonavir.
- Indinavir.
Ritonavir is commonly used at low doses as a pharmacokinetic booster rather than as the principal active antiretroviral agent.
Indinavir and some older protease inhibitors are now used infrequently.
Important Adverse Effects
- Gastrointestinal disturbance.
- Dyslipidaemia.
- Insulin resistance.
- Drug–drug interactions.
- Hyperbilirubinaemia with atazanavir.
- Nephrolithiasis with indinavir.
D. Fusion Inhibitors
Fusion inhibitors prevent HIV from fusing with the host cell membrane.
The classical example is enfuvirtide (T-20).
Enfuvirtide binds to the viral gp41 protein, preventing membrane fusion and viral entry.
Important Characteristics
- Administered by subcutaneous injection.
- Primarily used in selected treatment-experienced patients.
- Injection-site reactions are common.
E. Integrase Strand Transfer Inhibitors (INSTIs)
INSTIs are now central to many first-line ART regimens.
They inhibit HIV integrase, preventing the insertion of viral DNA into the host genome.
Examples
- Dolutegravir.
- Bictegravir.
- Raltegravir.
- Cabotegravir.
Important Considerations
- High antiviral efficacy.
- Generally good tolerability.
- Drug interactions with polyvalent cations.
- Possible weight gain with some regimens.
- Occasional neuropsychiatric adverse effects.
F. Other Entry and Attachment Inhibitors
Additional agents may be used in selected patients, particularly those with multidrug-resistant HIV.
- Maraviroc: CCR5 antagonist.
- Fostemsavir: gp120 attachment inhibitor.
- Ibalizumab: post-attachment inhibitor.
- Lenacapavir: capsid inhibitor that disrupts multiple stages of the HIV life cycle.
These drugs are not interchangeable with standard first-line regimens. Selection depends on clinical indications, resistance testing and other factors.
4. Where Antiretroviral Drugs Act in the HIV Life Cycle
Simplified HIV replication cycle and major antiretroviral drug targets.
| Stage | Drug Class | Example |
|---|---|---|
| Attachment and entry | CCR5 antagonists, attachment inhibitors | Maraviroc, fostemsavir |
| Membrane fusion | Fusion inhibitors | Enfuvirtide |
| Reverse transcription | NRTIs | Zidovudine, lamivudine, tenofovir |
| Reverse transcription | NNRTIs | Efavirenz, nevirapine |
| Integration | INSTIs | Dolutegravir, bictegravir |
| Viral maturation | Protease inhibitors | Darunavir, atazanavir |
5. Prevention of Opportunistic Infections
Effective ART is the most important long-term intervention for preventing HIV-associated opportunistic infections.
Additional antimicrobial prophylaxis may be indicated according to CD4 count, viral load, previous opportunistic infections and other risk factors.
A. Pneumocystis jirovecii Pneumonia (PCP) Prophylaxis
PCP is an AIDS-defining fungal infection, particularly associated with CD4 counts below 200 cells/mm³.
Indications for Primary Prophylaxis
Under commonly used adult HIV guidelines, primary PCP prophylaxis is indicated when:
- CD4 count is below 100 cells/mm³, regardless of viral load.
- CD4 count is between 100 and 200 cells/mm³ and plasma HIV RNA remains detectable.
Some local guidelines use a simpler threshold of CD4 below 200 cells/mm³.
B. Co-trimoxazole (TMP-SMX)
Co-trimoxazole, also called trimethoprim-sulfamethoxazole (TMP-SMX), is the preferred agent for PCP prophylaxis.
Common Prophylactic Regimen
One double-strength tablet containing 160 mg trimethoprim and 800 mg sulfamethoxazole orally once daily is a commonly used regimen.
Advantages
- Prevents PCP.
- Provides additional protection against toxoplasmosis when the appropriate regimen is used.
- Has activity against some bacterial infections.
Important Adverse Effects
- Skin rash.
- Bone marrow suppression.
- Hyperkalaemia.
- Renal-related adverse effects.
C. Pentamidine
Aerosolised pentamidine may be used as an alternative when TMP-SMX cannot be tolerated and other suitable options are unavailable or inappropriate.
Common Prophylactic Regimen
Aerosolised pentamidine 300 mg by inhalation every four weeks is a commonly used regimen.
Limitations
- Less comprehensive protection than TMP-SMX.
- Does not prevent toxoplasmosis.
- May cause cough and bronchospasm.
- Requires specialised nebuliser administration.
Other alternatives include atovaquone and dapsone-based regimens. G6PD testing is required before dapsone use.
D. When Can PCP Prophylaxis Be Stopped?
Primary PCP prophylaxis can generally be discontinued after effective ART produces sustained immune recovery, commonly when the CD4 count rises to at least 200 cells/mm³ for three months or longer.
Selected patients with CD4 counts between 100 and 200 cells/mm³ and sustained undetectable viral loads may also be eligible for discontinuation under specialist guidance.
Illustration: PCP Prophylaxis Pathway
6. Other Important Opportunistic Infection Prophylaxis
| Infection | Typical Indication | Prevention |
|---|---|---|
| PCP | Significant CD4 depletion, commonly below 200 with guideline-specific viral-load criteria | TMP-SMX |
| Toxoplasma encephalitis | CD4 below 100 and positive Toxoplasma IgG | TMP-SMX |
| Disseminated MAC | CD4 below 50 when effective suppressive ART is not being promptly initiated, after excluding active MAC | Azithromycin or clarithromycin |
| Latent tuberculosis | Positive screening or qualifying exposure after active TB is excluded | Appropriate TB preventive therapy |
Routine primary prophylaxis against disseminated MAC is generally unnecessary when effective ART is initiated promptly.
7. Comparison of Antiretroviral Drug Classes
| Drug Class | Mechanism | Examples | Important Adverse Effects |
|---|---|---|---|
| NRTIs | Viral DNA chain termination | Zidovudine, lamivudine, tenofovir | Bone marrow, renal or bone toxicity depending on drug |
| NNRTIs | Allosteric reverse transcriptase inhibition | Efavirenz, nevirapine | Rash, hepatotoxicity, neuropsychiatric effects |
| PIs | Inhibit viral protein cleavage and maturation | Darunavir, atazanavir, ritonavir | Metabolic effects, drug interactions |
| Fusion inhibitors | Inhibit gp41-mediated fusion | Enfuvirtide | Injection-site reactions |
| INSTIs | Inhibit viral DNA integration | Dolutegravir, bictegravir | Drug interactions, possible weight gain |
| CCR5 antagonists | Block CCR5-mediated entry | Maraviroc | Drug interactions; requires suitable viral tropism |
8. High-Yield Examination Summary
Antiretroviral Therapy
- ART is recommended for all people with HIV, regardless of CD4 count.
- The primary aim is sustained viral suppression.
- Standard initial treatment commonly consists of two NRTIs plus an INSTI.
- ART suppresses HIV but does not eradicate latent viral reservoirs.
Drug Mechanisms
- NRTIs: inhibit viral DNA synthesis through chain termination.
- NNRTIs: allosterically inhibit reverse transcriptase.
- PIs: inhibit viral maturation.
- Fusion inhibitors: block viral entry through gp41.
- INSTIs: prevent integration of viral DNA into host DNA.
Opportunistic Infection Prevention
- Co-trimoxazole is the preferred PCP prophylactic agent.
- Aerosolised pentamidine is an alternative but does not prevent toxoplasmosis.
- PCP prophylaxis is particularly relevant in patients with CD4 counts below 200 cells/mm³.
- Effective ART and immune restoration reduce the need for ongoing prophylaxis.
The older recommendation to initiate ART only when CD4 falls below 350 cells/mm³ is obsolete. Modern treatment recommends ART for everyone with HIV. For PCP prevention, co-trimoxazole remains the preferred prophylactic agent, with eligibility determined by CD4 count, viral suppression and clinical history.
Antiretroviral regimens and opportunistic infection prophylaxis require individual assessment of resistance, coinfections, renal and hepatic function, drug interactions and current local guidelines. Patients should not stop or modify ART without medical supervision.
Kembara Xtra – Medicine Revision Notes